Nonserious Infections. Should There Be Cause for Serious Concerns?

Kathryn H. Dao; Morley Herbert; Nadia Habal; John J. Cush

doi:10.1016/j.rdc.2012.08.016

Nonserious Infections. Should There Be Cause for Serious Concerns?

Kathryn H. Dao, Morley Herbert, Nadia Habal, John J. Cush

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the impact of immunosuppression, particularly with tumor necrosis factor inhibitors (TNFi), on these infections. A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab.

Original language	English (US)
Pages (from-to)	707-725
Number of pages	19
Journal	Rheumatic Disease Clinics of North America
Volume	38
Issue number	4
DOIs	https://doi.org/10.1016/j.rdc.2012.08.016
State	Published - Nov 2012
Externally published	Yes

Keywords

Adalimumab
Anti-TNF
Etanercept
Infliximab
Nonserious infections
Rheumatoid arthritis
Safety

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1016/j.rdc.2012.08.016

Fingerprint Dive into the research topics of 'Nonserious Infections. Should There Be Cause for Serious Concerns?'. Together they form a unique fingerprint.

Cite this

@article{05f4a996f6ef4f71a62c48631b7f5aaa,

title = "Nonserious Infections. Should There Be Cause for Serious Concerns?",

abstract = "Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the impact of immunosuppression, particularly with tumor necrosis factor inhibitors (TNFi), on these infections. A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab.",

keywords = "Adalimumab, Anti-TNF, Etanercept, Infliximab, Nonserious infections, Rheumatoid arthritis, Safety",

author = "Dao, {Kathryn H.} and Morley Herbert and Nadia Habal and Cush, {John J.}",

year = "2012",

month = nov,

doi = "10.1016/j.rdc.2012.08.016",

language = "English (US)",

volume = "38",

pages = "707--725",

journal = "Rheumatic Disease Clinics of North America",

issn = "0889-857X",